Summary of Compugen Conference Call Company Overview - **Company**: Compugen (NasdaqCM:CGEN) - **Industry**: Biotechnology, specifically in immuno-oncology - **Key Focus**: Computational AI-based target discovery for new drug targets Core Points and Arguments 1. **Unique Computational Platform**: Compugen utilizes a validated computational platform to identify first-in-class drug targets in immuno-oncology, including TIGIT and PVRIG [3][4] 2. **Pipeline Assets**: The company has two wholly owned assets, COM-902 (TIGIT blocker) and COM-701 (anti-PVRIG antibody), and has licensed COM-902 to AstraZeneca for use in their bispecific therapy [4][34] 3. **Clinical Trials**: - COM-701 is being evaluated in recurrent platinum-sensitive ovarian cancer, with promising early clinical signals observed, particularly in PD-1 negative patients [5][6][7] - The trial design includes an adaptive approach with a control arm expected to show a median progression-free survival (PFS) of 5.5 months [11][12] - Results from the trial are anticipated in Q1 2027 [12][18] 4. **Biological Mechanism**: PVRIG inhibition is believed to significantly increase T cell presence in the tumor microenvironment, which is critical for efficacy in ovarian cancer [6][9] 5. **Regulatory Considerations**: A three-month improvement in PFS over the control arm could initiate discussions with the FDA regarding accelerated approval due to the unmet need in this patient population [23][24] 6. **Partnership with AstraZeneca**: Compugen has received $30 million in milestones from AstraZeneca and is eligible for an additional $170 million, along with mid-single digit tiered royalties from potential sales of volrustomig [42][44] Additional Important Information 1. **Competitive Landscape**: Compugen is currently the only company with a PVRIG targeting antibody in clinical trials, following GSK's discontinuation of their PVRIG program [28][31] 2. **TIGIT Development**: The company has paused new trials for COM-902 due to ongoing debates in the community regarding TIGIT therapies, but sees future potential based on AstraZeneca's promising results [34][38] 3. **IL-18BP Asset**: Compugen has licensed an IL-18BP blocker to Gilead, which is currently in phase one trials, with a unique mechanism to activate IL-18 in the tumor microenvironment [50][51] 4. **Cash Runway**: Compugen has a cash runway of approximately two years, extending into Q3 2027, allowing for the continuation of current trials without additional income [61] Conclusion Compugen is positioned as a pioneer in computational drug discovery within the immuno-oncology space, with a robust pipeline and strategic partnerships that could lead to significant advancements in cancer treatment. The upcoming trial results and ongoing collaborations will be critical in shaping the company's future trajectory and market position.

Vilastobart Clinical Data and Opportunity - Vilastobart, in combination with atezolizumab, showed a 40% Overall Response Rate (ORR) in MSS mCRC patients without liver metastases and with high plasma TMB[30, 42] - 63% of plasma TMB-evaluable patients had high plasma TMB (≥10 mutations/Mb) in the Phase 2 trial, including all TMB-evaluable responders[32, 33, 42] - A statistically significant correlation (p=0.05) was observed between plasma TMB status and response to vilastobart plus atezolizumab[33, 42] - The combination of vilastobart and atezolizumab demonstrated a differentiated safety profile, with a low discontinuation rate of 5% and only 7% of patients experiencing colitis of any grade[35, 36, 42] Market and Competitive Landscape - Approximately 95% of mCRC patients are MSS, and standard of care in 3L+ provides minimal benefit (1-6% ORR)[23] - Real-world data indicates that approximately 55% of patients with MSS CRC have high plasma TMB, which is substantially higher than historically reported with tissue-based TMB assays[28, 42] - Next-generation anti-CTLA-4 agents in development show promising clinical efficacy in MSS mCRC, with ORRs ranging from 8-29% and discontinuation rates due to AEs up to ~30%[21] Technology and Pipeline - Xilio's clinically-validated platform technology is being applied across diverse mechanisms and architectures, including antibodies, cytokines, bispecifics, and T cell engagers[13, 14] - Efarindodekin Alfa (tumor-activated IL-12) demonstrated promising clinical efficacy with a generally well-tolerated safety profile in Phase 1 in patients with advanced solid tumors[44] - Masked T cell engager programs demonstrated potent anti-tumor activity with favorable tolerability across a diverse range of targets in preclinical models[50, 51, 52] Financial Outlook and Milestones - The company anticipates a cash runway into Q1 2027, including a $175 million development milestone received under the Gilead license in Q4 2025[53] - Anticipated milestones include reporting updated Phase 2 data for vilastobart in combination with atezolizumab in metastatic MSS mCRC in 1H 2026 and IND submissions for at least two masked T cell engager programs in 2027[53]

Group 1 - The company is engaged in ongoing and constructive discussions with the U.S. administration regarding Medicaid exposure, indicating a proactive approach to policy changes [1][2] - The senior team is actively meeting with key stakeholders in Washington D.C., emphasizing the importance of these relationships in navigating the regulatory landscape [2] - The administration aims to avoid actions that could harm the sector and innovation, suggesting a supportive environment for companies in the industry [3]

Summary of Gilead Sciences Conference Call Company Overview - **Company**: Gilead Sciences (NasdaqGS: GILD) - **Date of Conference**: November 10, 2025 Key Industry Insights - **Policy Environment**: Ongoing discussions with the U.S. administration regarding Medicaid and pricing disparities between the U.S. and Europe, with a focus on maintaining innovation in the biotech sector [6][7][8] - **R&D Commitment**: Gilead has committed $32 billion to U.S. R&D and manufacturing investments over the next five years [8] Core Business Segments HIV Business - **Market Position**: Gilead has the largest HIV treatment and prevention business, with a projected 5% growth in 2025 despite headwinds from Medicare Part D reforms [12][23] - **Yeztugo Launch**: Yeztugo, a new long-acting HIV prevention injection, generated $39 million in sales in Q3 and is expected to reach $150 million for the year [15][17] - **Access and Adoption**: Over 75% access to covered lives in the U.S. achieved within three months of launch, with major Medicaid plans including Yeztugo on their formularies [17][22] - **Descovy Performance**: Descovy, the existing daily pill for HIV prevention, grew 32% year-over-year, contributing significantly to the overall HIV prevention business growth of 42% [14][26] Oncology and Liver Disease - **Livdelzi Performance**: Livdelzi, a drug for primary biliary cholangitis, achieved $105 million in sales with a 35% quarter-over-quarter growth, partly due to the withdrawal of a competitor's product [42][44] - **Hepcludex Update**: Hepcludex for hepatitis D is expected to be refiled in the U.S. after successful performance in Europe, representing a growth opportunity in Gilead's liver portfolio [50][52] Cell Therapy - **Anito-cel Development**: Anito-cel, a BCMA cell therapy for multiple myeloma, is expected to launch in 2026, with potential for significant market share [55][56] - **Trodelvy Growth**: Trodelvy is projected to grow significantly as it moves into first-line treatment for triple-negative breast cancer, with a current run rate of approximately $1.4 billion [58][59] Financial Performance and Guidance - **Sales Growth**: Gilead's overall business is experiencing strong growth, particularly in HIV prevention and treatment, with a robust pipeline of new products [11][12][52] - **Capital Allocation Strategy**: Gilead plans to remain active in business development but will be selective due to a strong existing portfolio and no immediate patent cliffs until 2036 [65][68] Additional Considerations - **Market Dynamics**: Gilead is observing competitive pressures in the cell therapy market but remains committed to expanding its offerings [56][57] - **Therapeutic Focus**: The company will continue to focus on virology, liver disease, inflammation, and oncology, with no immediate plans to enter new therapeutic areas [70][71] This summary encapsulates the key points discussed during the conference call, highlighting Gilead Sciences' strategic direction, market performance, and future growth opportunities.

Core Viewpoint - The AIDS Healthcare Foundation (AHF) is launching a mobile billboard to criticize Gilead Sciences for its pricing strategy regarding the HIV prevention drug lenacapavir, demanding that it be made affordable and accessible [1] Group 1: Company Actions - AHF's mobile billboard will circle the venue of the Global Pharma & Biotech Summit in London on November 11-12 [1] - The billboard carries a message directed at Gilead and its CEO Daniel O'Day, urging them to "Make Lenacap" [1] Group 2: Industry Context - The event coincides with the Global Pharma & Biotech Summit, highlighting ongoing discussions in the pharmaceutical industry regarding drug pricing and accessibility [1]

Financial Performance - Total revenues for Q3 2025 were $7,769 million, a 3% increase from $7,545 million in Q3 2024[14] - Product sales decreased to $7,345 million in Q3 2025 from $7,515 million in Q3 2024, representing a decline of 2%[14] - Net income for Q3 2025 was $3,052 million, compared to $1,253 million in Q3 2024, marking a significant increase of 143%[14] - Basic earnings per share attributable to Gilead increased to $2.46 in Q3 2025 from $1.00 in Q3 2024[14] - The company reported a comprehensive income of $3,107 million for Q3 2025, compared to $1,233 million in Q3 2024[17] - For the nine months ended September 30, 2025, Gilead's net income was $6,327 million, compared to a net income of $1,253 million for the same period in 2024, marking a significant increase[20] - Total revenues for the nine months ended September 30, 2025, were $21,518 million, compared to $21,185 million in 2024, reflecting a growth of 1.6%[31] Assets and Liabilities - Total current assets decreased to $17,874 million as of September 30, 2025, down from $19,173 million at the end of 2024[12] - Total assets slightly decreased to $58,533 million as of September 30, 2025, compared to $58,995 million at the end of 2024[12] - Total liabilities decreased to $37,077 million as of September 30, 2025, down from $39,749 million at the end of 2024[12] - Long-term debt decreased to $22,135 million as of September 30, 2025, down from $24,896 million at the end of 2024[12] - The total stockholders' equity as of September 30, 2025, was $21,456 million, up from $18,390 million as of September 30, 2024, indicating a growth of about 11.5%[20] Cash Flow and Investments - Cash and cash equivalents at the end of the period were $7,330 million, up from $5,037 million at the end of the same period in 2024[25] - Net cash provided by operating activities for the nine months ended September 30, 2025, was $6,692 million, down from $7,853 million in the same period of 2024[25] - The company experienced a net cash used in investing activities of $2,958 million for the nine months ended September 30, 2025, compared to $3,224 million in the same period of 2024[25] - Net cash used in financing activities was $6,482 million for the nine months ended September 30, 2025, compared to $5,693 million in the same period of 2024[25] Research and Development - Research and development expenses for Q3 2025 were $1,346 million, a decrease from $1,395 million in Q3 2024[14] - Acquired in-process research and development expenses totaled $485 million for the nine months ended September 30, 2025, compared to $4,674 million in the same period of 2024[25] - A partial impairment charge of $190 million was recognized for the bulevirtide IPR&D intangible asset due to competitive market data[69] - A significant impairment charge of $2.4 billion was recorded for the NSCLC IPR&D intangible asset following the failure of the Phase 3 EVOKE-01 study[71] Stockholder Activities - Gilead declared dividends of $0.79 per share in Q3 2025, totaling $995 million, compared to $0.77 per share totaling $977 million in Q3 2024, reflecting a 1.6% increase in dividends declared[20] - The company repurchased common stock under repurchase programs at an average price of $113.25 per share, totaling $435 million in Q3 2025[20] - Gilead's stock-based compensation for the three months ended September 30, 2025, was $231 million, compared to $216 million for the same period in 2024, showing an increase of approximately 6.9%[20] Legal and Regulatory Matters - Gilead settled claims with the direct purchaser class and retailer opt-out plaintiffs for $525 million in May 2023, which was paid in the second half of 2023[88] - Approximately 23,000 active plaintiffs are involved in product liability lawsuits related to Viread, Truvada, Atripla, Complera, and Stribild, with a trial date set for March 2027 for the first bellwether trial in federal court[93] - The court dismissed the New Mexico Attorney General's case against Gilead with prejudice in September 2025, resolving that lawsuit[90] - Gilead intends to vigorously defend itself in ongoing legal actions, which could result in significant monetary damages if plaintiffs are successful[91] Market and Strategic Developments - A strategic partnership with LEO Pharma was established, involving a $250 million upfront payment and potential additional milestone payments of up to $1.5 billion[64] - Gilead acquired approximately 15.2 million additional shares of Arcus for $320 million, increasing its ownership to approximately 30%[65] - The company completed the acquisition of CymaBay Therapeutics, Inc. for total consideration of $3.9 billion in March 2024, which was accounted for as an asset acquisition[58] - In October 2025, the company acquired Interius BioTherapeutics, Inc. for approximately $350 million in cash consideration[57]

Core Viewpoint - Gilead Sciences announced that its breast cancer drug Trodelvy did not achieve the primary endpoint in a late-stage clinical trial [1] Company Summary - Gilead Sciences is facing a setback with its breast cancer treatment Trodelvy, as the drug failed to meet the main goal in a significant study [1]

Group 1: Gilead Sciences Inc - Gilead Sciences reported a revenue of $6.4 billion for the last quarter, reflecting a 5% increase year-over-year [1] - The company’s antiviral drug sales, particularly for HIV and COVID-19 treatments, contributed significantly to the revenue growth [1] - Gilead's pipeline includes promising candidates for oncology and inflammatory diseases, which may enhance future growth prospects [1] Group 2: Applied Materials Inc - Applied Materials achieved a revenue of $6.2 billion, marking a 10% increase compared to the previous year [1] - The semiconductor equipment segment showed strong demand, driven by advancements in AI and 5G technologies [1] - The company anticipates continued growth in the semiconductor market, supported by increased capital expenditures from major customers [1] Group 3: Salesforce Inc - Salesforce reported a revenue of $7.4 billion, up 14% year-over-year, driven by strong demand for its cloud-based solutions [1] - The company’s focus on expanding its product offerings and enhancing customer experience has led to increased customer retention [1] - Salesforce is investing in AI capabilities to further enhance its platform, which is expected to drive future growth [1]

Core Insights - Gilead Sciences, Inc. (GILD) reported a 3% year-over-year growth in total revenues for Q3 2025, driven by higher royalty, contract, and other revenues, alongside strong product sales from its HIV franchise and liver disease drug Livdelzi [1][10] Revenue Breakdown - Total revenues include product sales and royalty, contract, and other revenues [1] - Excluding Veklury, product sales increased by 4% to $7.1 billion [2] HIV Franchise Performance - Gilead's HIV franchise remains strong, with flagship therapies Biktarvy and Descovy contributing significantly to revenue growth [3] - Biktarvy sales rose 6% year-over-year to $3.7 billion, capturing over 52% of the U.S. treatment market [4] - Descovy sales increased by 20% year-over-year to $701 million, with approximately 75% of sales for HIV prevention [6] - Newly approved Yeztugo generated $39 million in sales, achieving a 75% coverage goal ahead of schedule [7] - Gilead anticipates approximately 5% HIV revenue growth in 2025, despite challenges from Medicare Part D redesign [7] Liver Disease Portfolio - Sales from the liver disease portfolio increased by 12% to $819 million, primarily due to demand for Livdelzi [9] - Livdelzi surpassed $100 million in quarterly sales for the first time and is now the first-line treatment for second-line PBC in the U.S. [10][11] Cell Therapy Franchise - Sales from the Cell Therapy franchise decreased by 11% to $432 million, missing consensus estimates [12] - Yescarta sales fell by 10% to $349 million, while Tecartus sales decreased by 15% to $83 million due to lower demand [12] Overall Performance and Market Position - Despite declines in Veklury and Cell Therapy sales, the strong performance of the HIV franchise and Livdelzi supports future growth [10][14] - Gilead's shares have surged 32.2% year-to-date, outperforming the industry growth of 12.1% [14]

Core Insights - IDEAYA Biosciences reported significant progress in its pipeline and business operations, including a partnership with Servier that extends its runway into 2030 and enables potential commercialization of darovasertib outside the U.S. [2] Pipeline Developments - The Phase 2/3 trial (OptimUM-02) of darovasertib/crizotinib in metastatic uveal melanoma is on track to report median progression-free survival (PFS) data by year-end 2025 to Q1 2026, with enrollment expected to be completed by year-end [4][5] - The single-arm Phase 2 trial (OptimUM-01) reported a median overall survival (OS) of 21.1 months and a median PFS of 7.0 months, with a confirmed overall response rate (ORR) of 34% [5] - IDEAYA has initiated a randomized Phase 3 trial (OptimUM-10) for darovasertib as a neoadjuvant therapy in primary uveal melanoma, targeting approximately 450 patients [8] Financial Highlights - As of September 30, 2025, IDEAYA had approximately $1.14 billion in cash, cash equivalents, and marketable securities, an increase from $991.9 million as of June 30, 2025, primarily due to a $210 million upfront payment from Servier [11] - Collaboration revenue for Q3 2025 totaled $207.8 million, compared to zero in the previous quarter, driven by the Servier license agreement [11] - The net income for Q3 2025 was $119.2 million, a significant improvement from a net loss of $77.5 million in Q2 2025 [14] License Agreement with Servier - IDEAYA entered into an exclusive license agreement with Servier for darovasertib outside the U.S., receiving an upfront payment of $210 million and being eligible for up to $320 million in milestone payments [10] Research and Development Expenses - R&D expenses for Q3 2025 totaled $83.0 million, an increase from $74.2 million in Q2 2025, primarily due to higher clinical trial and manufacturing expenses [12] General and Administrative Expenses - G&A expenses for Q3 2025 were $16.4 million, up from $14.6 million in Q2 2025, mainly due to increased legal and commercial preparation expenses [13]